Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Recruiting
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Recruiting
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Gender:
FEMALE
Ages:
Between 27 years and 45 years
Trial Updated:
03/25/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Immunization, HPV Infection, Human Papillomavirus
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Metroplex Clinical Research Center, Dallas, Texas
Conditions: Cutaneous Lupus Erythematosus (CLE)
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: Medical City Children's Dallas, Dallas, Texas
Conditions: Ductus Arteriosus, Patent
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Recruiting
This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas
Conditions: Glioma
Inappropriate Sinus Tachycardia Registry
Recruiting
The primary objective of this registry is to capture real-world safety and performance data on AtriCure devices used to ablate cardiac tissue when treating Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS). This is a retrospective and prospective, multicenter, US/OUS, observational data registry.
Gender:
ALL
Ages:
All
Trial Updated:
03/25/2025
Locations: Texas Cardiac Arrhythmia Research Foundation, Austin, Texas
Conditions: Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Recruiting
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas
Conditions: Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
Effects of Obesity in the Aged
Recruiting
The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigators will use 1) continuous negative cuirass pressure, and 2) assisted biphasic cuirass ventilation to decrease obesity-related effects in older obese adults. Our approach will be to examine respiratory... Read More
Gender:
ALL
Ages:
Between 65 years and 75 years
Trial Updated:
03/25/2025
Locations: Institute for Exercise and Environmental Medicine, UT Southwestern and Texas Health Resources, Dallas, Texas
Conditions: Obesity, Aging
American Lung Association (ALA) Lung Health Cohort
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
03/25/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Lung Diseases
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UT Health San Antonio MD Anderson Cancer Center, San Antonio, Texas
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
Recruiting
The goal of this clinical research study is to learn if using advanced magnetic resonance imaging (AMRI) will improve the targeting of brain tumor needle biopsies compared to the standard targeting techniques. Researchers also want to learn how the results of the images and biopsies compare to each other to try to improve the way researchers and radiologists use AMRI images. This is an investigational study. The perfusion scan is not FDA approved or commercially available. It is currently only... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Brain Lesion
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Recruiting
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Glioma